A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib In Combination With Physician's Choice Of Enzalutamide Or Abiraterone Acetate/Prednisone In Metastatic Castration-resistant Prostate Cancer With Dna Damage Repair Deficiencies

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib In Combination With Physician's Choice Of Enzalutamide Or Abiraterone Acetate/Prednisone In Metastatic Castration-resistant Prostate Cancer With Dna Damage Repair Deficiencies

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TALAPRO-2
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Mar 2018 Planned End Date changed from 22 Jul 2023 to 17 Mar 2024.
    • 19 Mar 2018 Planned primary completion date changed from 29 Mar 2022 to 30 May 2022.
    • 12 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top